drugset / Trial / NCT00913393
Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.
Timeline
- Start
- 2009-02
- Primary completion
- 2010-06
- Completion
- 2010-06
Outcome
Outcome not reported
Stopped (Business): “Study was terminated early for business purposes and as a result of a strategic decision to shift focus to another indication.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pamrevlumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Pamrevlumab | Monoclonal antibody | 10 mg/kg | Intravenous |